Johnson & Johnson Says Multiple Myeloma Treatment Approved by European Commission
MT Newswires Live
Aug 21
Johnson & Johnson's (JNJ) Tecvayli plus daratumumab has been approved by the European Commission as a treatment for adults with relapsed or refractory multiple myeloma, the company said Friday.
The approval was based on a 487-patient phase 3 study of the immunotherapy combination that showing statistically significant improvements in progression-free and overall survival versus standard of care treatments, the company said
The two drugs complement each other with daratumumab modulating the immune system to enhance T-cell fitness and activation, amplifying teclistamab's killing of myeloma cells, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.